Prognostic Value of Plasma Epstein–Barr Virus DNA for Local and Regionally Advanced Nasopharyngeal Carcinoma Treated With Cisplatin-Based Concurrent Chemoradiotherapy in Intensity-Modulated Radiotherapy Era

Ítems similars

• The impact of the cumulative dose of cisplatin during concurrent chemoradiotherapy on the clinical outcomes of patients with advanced-stage nasopharyngeal carcinoma in an era of intensity-modulated radiotherapy
  per: Guo, Shan-Shan, et al.
  Publicat: (2015)
• Plasma Epstein-Barr viral DNA complements TNM classification of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy
  per: Zhang, Lu, et al.
  Publicat: (2015)
• Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA ≥4000 copies/ml: a matched study
  per: Guo, Shan-Shan, et al.
  Publicat: (2016)
• Induction chemotherapy followed by radiotherapy concurrent chemoradiotherapy in the treatment of different risk locoregionally advanced nasopharyngeal carcinoma
  per: Li-Ting Liu, et al.
  Publicat: (2020-06-01)
• Induction chemotherapy followed by radiotherapy versus concurrent chemoradiotherapy in the treatment of different risk locoregionally advanced nasopharyngeal carcinoma
  per: Liu, Li-Ting, et al.
  Publicat: (2020)